C
Christopher B. Black
Researcher at Life Technologies
Publications - 11
Citations - 755
Christopher B. Black is an academic researcher from Life Technologies. The author has contributed to research in topics: In vivo & Bile acid. The author has an hindex of 8, co-authored 11 publications receiving 707 citations.
Papers
More filters
Journal ArticleDOI
Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel
Deshi Shi,Jian Yang,Dongfang Yang,Edward L. LeCluyse,Christopher B. Black,Li You,Fatemeh Akhlaghi,Bingfang Yan +7 more
TL;DR: Con concurrent use of both drugs would inhibit the activation of oseltamivir, thus making this antiviral agent therapeutically inactive, which is epidemiologically of significance because people who receive osel Tamsivir and clopidogrel simultaneously may maintain susceptibility to influenza infection or a source of spreading influenza virus if already infected.
Journal ArticleDOI
Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol
Man Tang,Madhu Mukundan,Jian Yang,Nathan Charpentier,Edward L. LeCluyse,Christopher B. Black,Dongfang Yang,Deshi Shi,Bingfang Yan +8 more
TL;DR: The isoform-specific hydrolysis of aspirin and clopidogrel suggests that these two antithrombogenic agents may have pharmacokinetic interactions with different sets of ester drugs, and the altered Hydrolysis by polymorphic mutants provides a molecular explanation to the interindividual variation.
Journal ArticleDOI
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Jasminder Sahi,Christopher B. Black,Geraldine A. Hamilton,Xianxian Zheng,Summer Jolley,Kelly Rose,Darryl Gilbert,Edward L. LeCluyse,Michael Sinz +8 more
TL;DR: The results suggest that other thiazolidinediones may have the potential to cause clinically significant drug interactions at sufficiently high doses and there is potential for interactions with CYP2C8 substrates.
Journal ArticleDOI
Aldehyde Oxidase Activity and Inhibition in Hepatocytes and Cytosolic Fraction from Mouse, Rat,Monkey and Human
TL;DR: Cryopreserved hepatocytes and cytosolic fractions from animals and humans provide qualitatively similar data within the species, indicating that results from animal studies cannot be safely extrapolated to humans.
Journal ArticleDOI
Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
Jasminder Sahi,Michael Sinz,Scott D. Campbell,Rouchelle J. Mireles,Xianxian Zheng,Kelly Rose,Shamsi Raeissi,Muhammed F. Hashim,Yuyang Ye,Sonia M. de Morais,Christopher B. Black,Meera Tugnait,Laurence H. Keller +12 more
TL;DR: The data indicates that CI-1034 is an inhibitor of major hepatic transporters and inhibition of bile efflux may have contributed to the observed clinical hepatotoxicity, and recommends that in vitro drug-drug interaction panels include inhibition and induction studies with transporter and drug metabolizing enzymes.